Letrozole
لتروزول
🎗️ Antineoplastic And Immunomodulating AgentsAromatase inhibitor
Market / country: 🇺🇸 USA
Femara (US)
🧮 Dose calculator
Breast cancer (hormonal therapy) · Regimen source: FDA Letrozole · 2.1
- • Cirrhosis or severe hepatic impairment: 2.5 mg every other day. Use for infertility is not in the FDA label. FDA Letrozole · 2.5
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Pregnancy (fetal harm); hypersensitivity. FDA Letrozole · 4
Formulations
- 2.5 mg tablet — tablet 🇺🇸 USA FDA Letrozole · 3
👥 Special populations
- 🤰 PregnancyContraindicated
Label: contraindicated in pregnancy. FDA Letrozole · 4
“Pregnancy: Letrozole can cause fetal harm [see Use in Specific Populations (8.1) ] .”
- 🤱 BreastfeedingDangerous / avoid
Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Letrozole · 8.2
“Because of the potential for serious adverse reactions in breastfed infants from letrozole, advise lactating women not to breastfeed while taking letrozole and for at least 3 weeks after the last dose.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Letrozole · 8.4
“The safety and effectiveness in pediatric patients have not been established.”
- 👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Letrozole · 8.5
“However, in comparison to tamoxifen, no overall differences with regards to the safety and efficacy profiles were observed between elderly patients and younger patients.”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Letrozole · 8.3
“Contraception Females Based on animal studies, letrozole tablets can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] .”
🔗 Reference links
- FDA (approval record)ANDA200161
- DailyMed (FDA label)FDA Letrozole
- MedlinePlus (NIH)Letrozole
- WHO ATC/DDDL02BG04
- Darooyab (Iran)Letrozole
🇮🇷 Registered in Iran Darooyab · G-1019/Letrozole
Dosage forms with Iranian generic codes, per Darooyab.
- 01922 · LETROZOLE 2.5MG TAB · قرص لتروزول ۲٫۵ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Letrozole · 3FDA Letrozole · 2.1FDA Letrozole · 2.5FDA Letrozole · 4FDA Letrozole · 8.2FDA Letrozole · 8.4FDA Letrozole · 8.5FDA Letrozole · 8.3FDA Letrozole · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1019/Letrozole
- Clinical review⚠ Unverified